Bradley Fox, MD
Family Medicine · Erie, PANPI 1336124247
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Astellas Pharma US Inc accounts for 78.3% of it on its own, with 19 other manufacturers making up the rest. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $370.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$46K
- Johnson & Johnson$11K
- Esperion Therapeutics, Inc.$248
- Pfizer$171
- Axsome Therapeutics, Inc.$154
- Dexcom, Inc.$125
- plus $806 from 14 others
Across 193 payments — averaging $8434.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- GSK$28K
- Eisai Inc.$4K
- AstraZeneca$1K
- Valneva Austria GmbH$720
What the payments were for
- Consulting fees$12,05921%
- Speaking & faculty fees$33,20357%
- Travel & lodging$9,22316%
- Food & beverage$3,9777%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 52 | $45,835 |
| Johnson & Johnson | 38 | $11,233 |
| Esperion Therapeutics, Inc. | 3 | $248 |
| Pfizer | 18 | $171 |
| Axsome Therapeutics, Inc. | 2 | $154 |
| Dexcom, Inc. | 1 | $125 |
| Exact Sciences | 1 | $124 |
| Phathom Pharmaceuticals, Inc. | 1 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $106 |
| Novo Nordisk | 6 | $95 |
| Lilly USA, LLC | 6 | $89 |
| Amarin Pharma, Inc. | 4 | $57 |
| Amgen | 3 | $51 |
| Astellas Pharma Global Development | 1 | $41 |
| Bayer | 2 | $34 |
| Merck | 2 | $32 |
| Boston Scientific | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| AbbVie | 1 | $16 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$39,149
- INVOKANA$10,610
- NEXLIZET$242
- NEXLETOL$242
- DEXCOM G7 GSS (161)$125
- DEXCOM STELO GLUCOSE BIOSENSOR$125
- XARELTO$124
- Symbravo$124
- VOQUEZNA$115
How this compares
$58,571 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 79 | $86,880 |
| MounjaroTirzepatide | 49 | $67,835 |
| JardianceEmpagliflozin | 49 | $61,775 |
| TrulicityDulaglutide | 41 | $50,633 |
| EliquisApixaban | 46 | $49,721 |
| ProliaDenosumab | 30 | $48,816 |
| JanuviaSitagliptin Phosphate | 33 | $37,440 |
| TradjentaLinagliptin | 27 | $32,199 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $24,710 |
| MyrbetriqMirabegron | 26 | $24,407 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $24,020 |
| Repatha SureclickEvolocumab | 20 | $15,401 |
| OzempicSemaglutide | 11 | $12,389 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $9,825 |
| Aripiprazole | 16 | $8,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $89 | $118,46890 claims |
| Johnson & JohnsonXarelto | $11,233 | $86,88079 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $11 | $63,430102 claims |
| PfizerEliquis | $171 | $49,72146 claims |
| AmgenProlia | $51 | $48,81630 claims |
| MerckJanuvia | $32 | $37,44033 claims |
| Astellas Pharma US IncMyrbetriq | $45,835 | $24,40726 claims |
| Novo NordiskOzempic | $95 | $12,38911 claims |
| AbbVieSynthroid | $16 | $2,53644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Erie
- Pamela BeckErie$31K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.